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Abstract
OBJECTIVE: To systematically assess the clinical ef-
fectiveness of traditional Chinese medicine (TCM)
in the treatment of functional dyspepsia (FD) of liv-
er-stomachdisharmonysyndromebymeta-analysis.
METHODS: Random controlled trials (RCTs) were
retrieved from databases, including Pubmed, China
national knowledge infrastructure, Wanfang Data,
VIP Information, and the Cochrane Library. Trials
were selected according to inclusion criteria. The ef-
fects of traditional Chinese medicine (TCM) versus
prokinetic agents in the treatment of functional
dyspepsia (FD) of liver-stomach disharmony syn-
drome were compared by meta-analysis. RevMan
5.0.24 was used for data analysis. The effective rate
was assessed by odds ratios (ORs), and 95% confi-
dence intervals (CIs) were calculated. The cure rate
was analyzed by the Peto OR. Simple statistical anal-
ysis was chosen to assess the frequency of pre-
scribed Chinese herbs in treating this syndrome.
RESULTS: Thirteen trials were included, involving
1153 patients, and these were of poor methodolog-
ical quality. Twelve studies mentioned the effective
rate and cure rate. TCM therapy showed a better
clinical effect rate compared with that with proki-
netic agents [OR: 3.2, 95% CI (2.27, 4.51)]. The TCM
group also had a better cure rate than that in the
group of prokinetic agents [Peto OR: 2.26, 95% CI
(1.61, 3.18)]. With regard to the frequency of Chi-
nese herbs used in these 13 trials, Baishao (Radix
Paeoniae), Chaihu (Radix Bupleuri), and Gancao (Ra-
dix Glycyrrhizae) were mostly prescribed, followed
by Xiangfu (Rhizoma Cyperi), Zhishi (Fructus Auran-
tii Immaturus), Zhiqiao (Fructus Aurantii), Foshou
(Citrus medica var.sarcodactylis), and Chenpi (Peri-
carpium Citri Reticulatae). No serious adverse ef-
fects were reported.
CONCLUSION: TCM therapy shows a superior effec-
tive rate and cure rate compared with those in pro-
kinetic agents in the treatment of FD of liver-stom-
ach disharmony syndrome. However, further strict-
ly designed RCTs are required because of the poor
quality of included trials.
© 2012 JTCM. All rights reserved.
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INTRODUCTION
Functional dyspepsia (FD) is defined as the presence of
gastrointestinal symptoms, such as epigastric pain, epi-
gastric burning, postprandial fullness, and early satia-
tion, nausea or vomiting in the absence of any organic,
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systemic, or metabolic disease.1 The pathophysiology
of FD has been widely investigated, but is still not well
identified.2
FD is frequently encountered in clinical practice. FD
was found to affect up to 23.5% of the population in a
study in Guangzhou, China.3 A large population-based
study in Europe showed that 20.6% of patients had
suffered from epigastric symptoms during the preced-
ing 12-month period.4
Although there is no specific remedy for FD, it is be-
lieved that improvement of living habits and psycholog-
ical management are beneficial to these patients.5 Rou-
tine therapies commonly used are eradication of Heli-
cobacter pylori, dopaminergic receptor blockers, sucral-
fate, and bismuth subsalicylate, or even antidepres-
sants. Some patients may be symptom-free for years,
while some continue to be symptomatic without the
help of medicine. TCM also plays an important role in
improving the symptoms of FD in the Chinese main-
land. In TCM, FD is considered as nearly equivalent
to the TCM term "stuffiness and fullness",6 which is di-
vided into different syndromes according to different
clinical symptoms and signs. The basic syndromes in-
clude liver-stomach disharmony syndrome, fluid and
food retention syndrome, dampness-heat of spleen and
stomach syndrome, cold and heat in complexity syn-
drome, and spleen-stomach weakness syndrome.7 The
syndrome of liver-stomach disharmony and spleen-
stomach weakness syndrome are predominant among
those FD outpatients.8 Epidemiology shows some rela-
tion between the occurrence of dyspepsia and recent
events in a patient's life, as well as psychosocial factors.9
Additionally, 54.2% of inpatients with FD have mood
disturbances,3 implying that emotional instability
might be the cause of some symptoms of FD. In the
theory of TCM, emotional instability is closely related
to disorder of liver-Qi, which leads to the syndrome of
liver-stomach disharmony.
To determine whether TCM offers advantages over rou-
tine Western Medicine in treating FD with liver-stom-
ach disharmony syndrome, we undertook a systematic
review and meta-analysis of all relevant randomized
controlled trials (RCTs).
METHODS
Search strategy
We identified studies by searching the following data-
bases: Pubmed, China national knowledge infrastruc-
ture Data-base (1994 to May 2012), Wanfang Data
(1989 to May 2012), VIP Information (1989 to May
2012), and the Cochrane Library. Search terms were
"functional dyspepsia", "liver-stomach disharmony"
and "disharmony between the liver and stomach", and
"random control", "clinical trial", and "TCM". Studies
published in English and Chinese were considered, and
only data available in the full text were reviewed.
Inclusion and exclusion criteria
Studies were eligible for inclusion in the meta-analysis
if they met all of the following criteria: 1) the study
was designed as an RCT; 2) patients included in the study
were diagnosed with FD according to Rome III,10 and
the TCM syndrome must be liver-stomach disharmony;6
3) TCM versus prokinetic agents was investigated; 4)
criteria for successful treatment were clearly stated and
treatment success was measured including the symp-
tom scores; and 5) the treatment course lasted for 2
weeks or more.
Trials were excluded for the following reasons: 1) stud-
ies were not RCTs; 2) the experimental group con-
tained both TCM and prokinetic agents; and 3) repeat-
edly published studies.
Data extraction
To avoid bias in the data extraction process, two review-
ers (Mingjin Zhu and Wei Xia) independently abstract-
ed and compared the results. All data were checked for
internal consistency, and disagreements were resolved
by discussion between the two reviewers and by seek-
ing the opinion of a senior reviewer (Chuijie Wang) if
necessary. Details abstracted from the studies, includ-
ing the name of the first author, year of publication,
number and mean age of the participants, male-female
ratio, and adverse reactions were listed. When more
than one published article described a single study, we
extracted data from the study providing the most de-
tailed information.
Assessment of methodological quality
Included RCTs were strictly evaluated according to
the methods of evaluating risk of bias as described in
the Cochrane Handbook 4.2.2 for Systematic Re-
views of Interventions (version 2004). The quality of
trials was assessed by examining: randomization, the
allocation concealment, baseline characteristics, blind-
ing, withdrawals/dropouts, and selective reporting of
outcomes, which were ranked by A (low risk of bi-
as), B (moderate risk of bias), and C (high risk of bi-
as). We also used the modified Jadad scoring system
for quality assessment.11
Data analysis
Review Manager 5.0.24 provided by the Cochrane Col-
laboration was used to analyze collected data. Odds ra-
tios (ORs) were used for dichotomous data, with 95%
confidence intervals (CIs). The Chi-squared test for ho-
mogeneity was carried out to determine whether the
distribution of results was compatible with the assump-
tion that differences between trials were due to chance
variation alone. Heterogeneity was presented as signifi-
cant when I2 was over 50% or P<0.1, and a random ef-
fect model was used for the meta-analysis. If I2 was less
than 50% and P>0.1, there was significant heterogene-
ity, and a fixed effect model was used. A funnel plot
was carried out to assess publication bias.12
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Sensitivity analysis
To evaluate the effect of methodological characteristics
of RCTs on the results of this meta-analysis, sensitivity
analysis was used to reanalyze the data by changing in-
clusion criteria or using different statistical methods. If
the sensitivity analysis was close to the results, this
strengthened the level of confidence.
RESULTS
In this review, 53 articles were retrieved from the five
above-mentioned electronic databases. Thirty-eight ar-
ticles were excluded by reading the headlines and ab-
stract, because they were not controlled trials (n=5),
they were not randomized (n=7), the experimental
group was TCM combined with other drugs (n=10),
both groups were TCM therapies (n=4), they con-
tained other TCM syndromes (n=10), or were duplicat-
ed articles (n=2). The rest of the 15 articles were care-
fully reviewed. Two articles described the same studies,
and therefore, we chose the detailed study. The other
excluded article showed different data between the ab-
stract and the content. Therefore, a total of 13 studies
involving 1153 patients were included in the systemat-
ic review.13-25 All 13 studies included were of a parallel
design, single center, and had a positive control group.
Trials were only performed in China and were written
in Chinese. The characteristics of included trials are
shown in Tables 1 and 2.
Methodological quality of included trials
All trails were of poor methodological quality and at
high risk of bias. Only one trial24 barely met the quality
grade B and with a modified Jadad score of 2 points,
while the rest were grade C with a modified Jadad
score of 1 point. All studies were described as random-
ized, but only four trials14,16,18,25 presented specific meth-
ods of allocation sequence. An RCT with high quality
and low bias should have blinding and allocation con-
cealment strictly designed and conducted. However,
none of the trials mentioned blinding and allocation
concealment. Dropouts were sometimes inevitable
when conducting clinical trials, and intention-to-treat
should be taken into consideration, but the identified
studies failed to provide any data on dropouts. Only
two studies21,24 mentioned adverse effects, while others
failed to provide any specific information about ad-
verse effects.
Effective rate meta-analysis
The 13 studies compared TCM interventions with pro-
kinetic agents, and 12 studies13-24 reported total effec-
tive rates: the group using TCM therapy varied from
83.3% to 93.33% , while the group of prokinetic
agents varied from 56.7% to 82.2% [OR: 3.2, 95%CI
(2.27, 4.51)]. There was no heterogeneity among trials
(χ2=3.34, P=0.99>0.1, I2=0% ), and therefore, the
M-H fixed-effect model was used. The tests for overall
effect showed that TCM therapy was better than proki-
netic agents, and there was a statistical significance in
effective rate (P<0.001) between the TCM group and
prokinetic agents (Figure 1). One study25 only com-
pared single symptoms separately. The bias of those 12
trials was that a funnel plot was used to assess publica-
tion bias (Figure 2). The funnel-shape was slightly
asymmetrical, indicating that there might be publica-
tion bias in those studies.
Cure rate meta-analysis
Nine studies13,16-18,20-24 described the cure rate. The Peto
fixed effects model is the more appropriate model for
rare events.26 The cure rate is a small probability event,
and therefore, we used the Peto OR to reduce bias.
The incorporated data showed that TCM therapy out-
weighed the prokinetic agents in curing FD (Peto OR:
2.26, 95%CI=[1.61, 3.18]), and there was no heteroge-
neity (χ2=3.15, P=0.92; I²=0%).
Subgroup analyses
Herbal therapy versus domperidone alone with 4
weeks' course: Eight studies13,14,16,17,20,21,23,24 compared
Chinese herbs alone with domperidone alone in a
4-week course. There was a significantly higher effec-
tive rate in herbal therapy than domperidone alone
[663 patients OR: 2.99, 95% CI (1.93, 4.63)], and
there was no significant heterogeneity (χ2=2.98, P=
0.89, I²=0%).
Herb therapy versus mosapride: Two studies18,19 com-
pared Chinese herbs with mosapride. The merged anal-
ysis showed that Chinese herbal medicine achieved a
higher response rate than mosapride [OR: 3.98, 95%
CI (1.50, 10.54)], and there was no significant hetero-
geneity (χ2=2.78, P=0.92, I²=0%) (Figure 3).
Sensitivity analyses
We renewed the analysis according to methodological
quality (with specific random method or follow-up).
Five14,16,18,24,25 of the studies with a relatively higher quali-
ty were selected, and their merged data showed that
there was a significant difference between TCM thera-
py and the control groups [OR: 3.37, 95%CI (1.72,
6.62]), and there was no significant heterogeneity in
this analysis (χ2=2.48, P=0.90, I² =0% ). This result
agrees with the whole analysis.
The selective ratio for single Chinese herbs in the
identified studies
The Chinese herbs were chosen by the researchers ac-
cording to the principle of TCM treatment in treating
liver-stomach disharmony syndrome, namely dispers-
ing the depressed liver-Qi and regulating the stomach.
To clearly understand Chinese herbal medicine, we per-
formed a simple statistical analysis on the frequency of
Chinese herbs used in these 13 trials. The distribution
of these herbs is shown in Figure 4. Baishao (Radix Pae-
oniae), Chaihu (Radix Bupleuri), and Gancao (Radix
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Figure 1 Comparison of the effective rate between the TCM group and prokinetic agents
0
0.2
0.4
0.6
0.8
1 0.1 0.2 0.5 1 2 5 10
Figure 2 Funnel plot of the effective rate between the TCM group and prokinetic agents
Figure 3 Subgroup analysis of the effective rate
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Glycyrrhizae) were mostly used, and the dosages were
9-15 g, 9-15 g, and 6-10 g, respectively.
DISCUSSION
Herbal medications provide symptom relief in FD, and
the evidence grade is moderate.27 They have a long his-
tory of use in the treatment of dyspeptic complaints.
Their mechanisms of action are not completely under-
stood. However, findings suggest that herbal medica-
tions might modulate the activity of the smooth mus-
culature of the digestive tract.28 The results of our me-
ta-analysis of data from 13 trials suggest that TCM has
higher effective and cure rates in treating FD of liv-
er-stomach disharmony syndrome than routine proki-
netic agents (domperidone or mosapride). However, all
identified studies were of poor quality. No study adopt-
ed blinding, concealment, and all the trials were con-
ducted from single centers, which all influenced the re-
liability of this systematic review.
There was no specific adverse effects mentioned in the
TCM group, and only one study mentioned that dom-
peridone had an adverse effect of epigastric discomfort
andmorepassing flatuses. Although some traditionalChi-
nese herbal medicines were reported to be toxic,29 herbal
medicine still plays an important role in treating chronic
diseases inChinawith fewer adverse effects reported.
Figure 4 shows the frequency of chosen herbs in treat-
ing FD with liver-stomach disharmony syndrome. The
frequently-used herbs (>6/13) were Baishao (Radix Pae-
oniae), Chaihu (Radix Bupleuri), Gancao (Radix Glyc-
yrrhizae), Xiangfu (Rhizoma Cyperi), Baizhu (Rhi-
zoma Atractylodis Macrocephalae), Zhishi (Fructus Au-
rantii Immaturus), Zhiqiao (Fructus Aurantii), Foshou
(Citrus Medica var. Sarcodactylis), and Chenpi (Peri-
carpium Citri Reticulatae), of which the major effects
are soothing the liver and regulating Qi. In addition,
these herbs constitute the majority of a famous tradi-
tional Chinese prescription called Chaihu Shugan Pow-
der (Bupleurm Powder for Dispersing Depressed Liv-
er-Qi), which relieves depression of the liver-Qi, and
promotes the circulation of Qi and relieves pain.30 This
treatment aims to treat the syndrome of stagnation of
Qi due to depression of the liver, focusing on the mani-
festations of stagnation of Qi and pain on the liver me-
ridian area. This review indirectly reveals that there is
close connection between the syndrome of stagnation
of Qi due to depression and the syndrome of liv-
er-stomach disharmony. The syndrome of stagnation
of Qi due to depression can lead to the syndrome of liv-
er-stomach disharmony according to the five-element
theory of TCM. In other words, this is called "wood re-
stricting earth". Therefore, dispersing the depressed liv-
er-Qi and regulating Qi for harmonizing the stomach
Figure 4 Frequency of single Chinese herbs chosen in the 13 included trials
aZhishi (Fructus Aurantii Immaturus), Zhiqiao (Fructus Aurantii), Foshou (Citrus medica var.sarcodactylis), and Chenpi (Pericarpium
Citri Reticulatae). bChaunxiong (Ligusticum chuanxiong Hort.), Chuanlianzi (Fructus Toosendan), and Banxia (Rhizoma Pinelliae).
cYujin (Radix Curcumae), Sugeng (Caulis Perillae), Shenqu (Massa Medicata Fermentata), Shanzha (Fructus Crataegi), Muxiang (Ra-
dix Aucklandiae), and Houpo (Magnolia officinalis Rehd. etWils). dSharen (Fructus Amomi), Maiya (Fructus Hordei Germinatus), Jin-
eijin (Endothelium Corneum Gigeriae galli), Huanglian (Coptis chinensis Franch), Fuling (Poria), Danggui (Radix Angelicae Sinen-
sis), Chenxiang (Aquilariae Lignum Resinatum), and Baihe (Lilium brownii var. viridulum).
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is a reasonable treatment for this syndrome.
Limitations of this systematic review
The main limitation of our review is in the low meth-
odological quality. The reason for this may be because
all of the studies were conducted in China and the re-
search might have specialized in TCM but lacked the
standard operation of RCTs. Most of the authors did
not know the correct method for generating a random-
ization sequence, while a few of them knew it, but did
not follow it properly.31 Some authors refuse to publish
negative results, which also causes bias. Every study re-
garded symptom scores as a leading indicator of thera-
peutic effect. Although a symptom score scale was sci-
entifically designed, it was still subjective and the
scores might easily have been affected by the patients
and researchers to some extent. Only three studies used
an objective observation indicator (gastric fluid empty-
ing rate, electrogastrogram, motilin, gastrin and gas-
tric emptying rate of barium strips). An objective crite-
rion is more persuasive.
Direction for future clinical research
Further exploration of trial design and standards for re-
porting trial results is required, and more high-quality
controlled trials are required for assessing the effects of
TCM compared with other drugs and placebo. All
RCTs should refer to the CONSORT (Consolidated
Standards of Reporting Trials) for TCM.32 The pre-
ferred research should be multicenter, and blinding,
concealment, and intention-to-treat are recommended
to raise the quality of RCTs. For scientific research, the
main outcome measures should be carefully considered
to make the research more objective and conceivable.
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